Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy and Safety Study of Daratumumab in Patients With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor [PI] and Immunomodulatory Drug [IMiD]) or Are Double Refractory to a PI and an IMiD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Documented multiple myeloma according to protocol-defined criteria~* Evidence of disease progression on the most recent prior treatment regimen based on International Myeloma Working Group criteria~* Eastern Cooperative Oncology Group performance status score of 0, 1, or 2~* Laboratory values and electrocardiogram within protocol-defined parameters at screening~Exclusion Criteria:~* Received daratumumab or other anti-CD38 therapies previously~* Nonsecretory multiple myeloma~* Previously received an allogenic stem cell transplant or has received an autologous stem cell transplantation within 12 weeks~* Exhibiting clinical signs of meningeal involvement of multiple myeloma~* Known chronic obstructive pulmonary disease, persistent asthma, or a history of asthma within 5 years~* Seropositive for human immunodeficiency virus, hepatitis B or antibodies to hepatitis B surface and core antigens, or hepatitis C~* Has plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes), or amyloidosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Part 1 (Type: EXPERIMENTAL): During Stage 1 of Part 1, participants will be randomized to receive daratumumab treatment regimens in Group A and Group B. If in Stage 1, 1 or both of the treatment groups is considered to be ineffective and/or not well tolerated, then that treatment group will be terminated. Participants in Group B will be given the option to cross over to Group A if the investigator deems it in the best interest of the participants.
- Part 2 (Type: EXPERIMENTAL): Based on the Part 1 response rate, Group A or B daratumumab treatment will be selected as the treatment regimen for participants enrolled in Part 2.

Based on this trial design, predict the completion outcome and termination type (if applicable).